Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_assertion type Assertion NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_head.
- NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_assertion description "[Moderately immunogenic HPV 16-associated murine tumour cell line mimicking human HPV 16-associated neoplasms TC-1 (MHC class I(+)) and its variants, TC-1/P3C10 and TC-1/A9, with a marked down-regulation of MHC I molecules, were used to examine the effect of local interleukin 12 (IL-12) gene therapy for the treatment of early tumour transplants and minimal residual tumour disease obtained after cytoreductive chemotherapy (CMRTD).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_provenance.
- NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_assertion evidence source_evidence_literature NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_provenance.
- NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_assertion SIO_000772 16328003 NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_provenance.
- NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_assertion wasDerivedFrom befree-20150227 NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_provenance.
- NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_assertion wasGeneratedBy ECO_0000203 NP457987.RAFLEoU-oDMGtD-V23alD6wiBjyO1U3FFlu7gK9tP8ro4130_provenance.